An examination of the current issues in testing and treating for Alpha-1 has been published by Robert A. Sandhaus, MD, PhD, in the journal Seminars in Respiratory and Critical Care Medicine.
Sandhaus is clinical director of the Alpha-1 Foundation, medical director of AlphaNet, and director of the Alpha-1 program at National Jewish Health, Denver.
The article, titled, “Alpha -1 Antitrypsin Deficiency: Whom to Test, Whom to Treat?” discusses the difficulty of large, long-term therapy trials in Alpha-1.
The article points out that family testing combined with genetic counseling can help an entire family avoid risk factors and monitor for disease.
In addition, the article concludes, “As additional genetic modifiers of COPD risk are identified, (Alpha-1) will be viewed as the model system, and its testing and treatment guidelines may find even wider application.”